Close

Natural Alternatives International v. Creative Compounds (BIO Brief as Amicus Curiae)

Natural Alternatives International v. Creative Compounds (BIO Brief as Amicus Curiae supporting appellant in the US Court of Appeals for the Federal Circuit)

BIO Statement on Opioid Crisis Response Act of 2018

Washington, DC (April 24, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding S. 2680, the Opioid Crisis Response Act of 2018:

BIO Submission to the China Section 301 Investigation - September 28, 2017

BIO submitted comments to the Office of the United States Trade Representative (USTR) and the inter-agency Section 301 Committee regarding the investigation, initiated on August 18, 2017,...

BIO Announces Keynote and Returns to Boston June 4-7 to Celebrate 25 Years of History-Making Innovation

TV's Robin Roberts will deliver the keynote address at the upcoming BIO International Convention which returns to Boston June 4-7. Celebrating its 25 year anniversary, BIO will host the event expected to attract more than 16,000 attendees and 1,800 exhibitors from 74 countries.

BIO Comments on FDA Draft Guidance Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products

March 27, 2018

...

BIO Comments on DOJ’s Environmental Settlement Agreement with Philadelphia Energy Solutions

BIO today submitted comments to the U.S. Department of Justice on the proposed Consent Decree and Environmental Settlement Agreement with the United States Bankruptcy Court for the District of Delaware in the case of Philadelphia Energy Solutions Refining and Marketing LLC and PES Holdings LLC (PES).

BIO Comments on Proposed Settlement Agreement Between EPA and Philadelphia Energy Solutions on RFS Obligations

BIO is greatly concerned by the Department of Justice's and Environmental Protection Agency's proposed Settlement Agreement to resolve a dispute about the PES Holdings' obligations under the Renewable Fuel Standard.

BIO Applauds Introduction of the Advancing Emergency Preparedness Through One Health Act of 2018

The Biotechnology Innovation Organization (BIO) applauds the introduction of the “Advancing Emergency Preparedness Through One Health Act of 2018” by Senators Tina Smith (D-MN) and Todd Young (R-IN).

Clinical Trials: BIO Comments on FDA Promoting the Use of Complex Innovative Designs in Clinical Trials

Re: Docket No. FDA-2018-N-0049: Promoting the Use of Complex Innovative Designs in Clinical Trials

...

BIO Statement on Growing American Food Exports Act of 2018

The Biotechnology Innovation Organization (BIO) today released the following statement in response to the introduction of the “Growing American Food Exports Act of 2018” by Representatives Neal Dunn (FL-02) and Jimmy Panetta (CA-20).